DNAJB1-PRKACA Fusion Kinase Peptide Vaccine
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for DNAJB1-PRKACA Fusion Kinase Peptide Vaccine, covering 2025-12-03 to 2026-02-24. Get the full timeline:
Most recent: Clinical Trial Update: A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) [Phase 1]